<DOC>
	<DOCNO>NCT02753946</DOCNO>
	<brief_summary>The purpose study demonstrate safety efficacy ZTI-01 ( IV fosfomycin ) non-inferior piperacillin/tazobactam overall success ( clinical cure microbiologic eradication ) treatment hospitalized patient complicate urinary tract infection ( cUTI ) acute pyelonephritis ( AP ) .</brief_summary>
	<brief_title>Safety Efficacy ZTI-01 ( IV Fosfomycin ) v Piperacillin/Tazobactam Treatment cUTI/AP Infections</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , parallel-group study evaluate safety , tolerability , efficacy , pharmacokinetics ZTI-01 ( IV fosfomycin ) compare piperacillin/tazobactam treatment hospitalize adult cUTI AP . Diagnosed prescreened hospitalized patient randomize 1:1 receive one two intravenous treatment : 6 g ZTI-01 three time daily ( 18g total daily dose ) 4.5 g piperacillin/tazobactam three time daily ( 13.5g total daily dose ) 7 calendar day , option extend treatment 14 day patient positive blood culture pretreatment . Patients participate study approximately 26 day . Urine culture obtain organism quantify qualified patient baseline , treatment , end treatment ( EOT ) , test cure ( TOC ) late follow visit ( LFU ) . Blood culture obtain baseline repeat positive throughout study . Safety efficacy evaluation include vital sign , lab , physical exam , ECG overall response evaluate Investigator . Pharmacokinetic sample obtain ( sparse sampling ) patient .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Pyelonephritis</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<mesh_term>Fosfomycin</mesh_term>
	<criteria>1 . A sign informed consent form ( ICF ) ; 2 . Male female , least 18 year age ; 3 . Diagnosis require hospitalization treatment intravenous ( IV ) antibiotic ; 4 . Documented suspected cUTI AP include least 2 protocol define sign symptom urine specimen evidence pyuria plus least one protocol define associate risk 5 . Pretreatment baseline urine culture specimen 6 . Expectation implant urinary instrumentation remove replace longer 24 hour , randomization ; 7 . Expectation patient survive anticipate duration study ; 8 . Patient require initial hospitalization manage cUTI AP ; 9 . Women childbearing potential negative pregnancy test randomization willing consistently use highly effective method contraception 10 . Male study participant require use condom spermicide throughout study 1 . Presence follow condition : perinephric abscess , renal corticomedullary abscess , uncomplicated urinary tract infection , recent history trauma pelvis urinary tract , polycystic kidney disease , chronic vesicoureteral reflux , previous plan renal transplantation ; patient receive dialysis/hemodialysis/CVVH , previous plan cystectomy ileal loop surgery ; know suspected infection ; cause pathogen resistant study treatment antibiotic 2 . Presence suspect confirmed acute bacterial prostatitis , orchitis , epididymitis , chronic bacterial prostatitis determine history and/or physical examination ; 3 . Gross hematuria require intervention ; 4 . Urinary tract surgery within 7 day prior randomization urinary tract surgery plan study period ; 5 . Creatinine clearance &lt; 20 mL/min use CockcroftGault formula ; 6 . Nonrenal source infection endocarditis , osteomyelitis , abscess , meningitis , pneumonia diagnose within 7 day prior randomization ; 7 . Signs severe sepsis define per protocol ; 8 . Pregnant breastfeeding woman ; 9 . Known seizure disorder require current treatment antiseizure medication would prohibit patient comply protocol ; 10 . Cancer chemotherapy , immunosuppressive medication transplantation , medication rejection transplantation 30 day randomization ; 11 . Significant hepatic disease dysfunction , include know acute viral hepatitis hepatic encephalopathy ; 12 . ALT/AST &gt; 5 × ULN total bilirubin &gt; 3 × ULN Screening ; 13 . Receipt potentiallyeffective systemic antibiotic activity Gramnegative uropathogens 24 hour within 72hour window prior randomization ( exception define protocol ) ; 14 . Requirement additional systemic antibiotic therapy ( study drug ) antifungal therapy vaginal candidiasis ; 15 . Likely require use antibiotic cUTI AP prophylaxis study ; 16 . Known history HIV virus infection know recent CD4 count &lt; 200/mm3 ; 17 . Presence significant immunodeficiency immunocompromised condition longterm use systemic corticosteroid ; 18 . Presence neutropenia ; 19 . Presence thrombocytopenia ; 20 . A QT interval correct use Fridericia 's formula &gt; 480 msec ; 21 . History significant hypersensitivity allergic reaction fosfomycin , contraindication use piperacillin/tazobactam ; 22 . Participation clinical study involve investigational medication investigational device within last 30 day prior randomization ; 23 . Inability , judgment Investigator , tolerate salt load require study drug administration ; 24 . Unable unwilling , judgment Investigator , comply protocol ; 25 . Any patient previously randomize study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>